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 Imprecision:
Intra-assay imprecision: 3.1% at 98.6 ± 3.1 and 7.3% at 274.4 ± 20.1 ng/mL.
Inter-assay imprecision: 5.9% at 80.9 ± 4.5 and 10.1% at 254.2 ± 25.6 ng/mL.
 Linear range was 0-500ng/mL.
 Lower and upper limit of quantification were 3.9 and 500 ng/mL.
 Cross-reactivity was assessed against human sera (10 anonymised NNUH patients
samples) containing raised thyroid antibody (TPO>150kU/L; ref range 0-34kU/L). No
samples showed elevated a-OPGAb concentration (green box-plot).
Assay Characteristics
 Serum samples were collected from healthy volunteers following and in accordance
with the Ministry of Defence Research Ethics Committee (MODREC-165). 321 serum
samples (241 men and 80 women, aged 17-32 years) were used to assess the
distribution of a-OPG Ab.
Determination of a-OPGAb reference intervals 
in healthy individuals
 Skewed distribution of a-OPGAb in healthy population
 Adult population would be considered positive with a titer above the cut-off limit (95%) of 
96ng/mL calculated using the geometric mean of log10 dataset
 4.3% of the population presented elevated a-OPGAb. There was no significant effect of 
gender on the distribution (♀:7.6%; ♂:5.3%).
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Association of a-OPGAb with bone turn-over 
markers in young and healthy population
Of aOPGAb positive samples 42.9% had CTX (bone-resorption marker) above the reference 
range and 71.4% had PINP (bone-formation marker) above the reference range.
No clear correlation was observed. 
 Auto-antibodies against Osteoprotegerin (a-OPGAb), by capturing OPG, enable
sustained interaction of RANKL with RANK and over-activation of osteoclasts.
 Such antibodies have been identified in 2009, in a man with coeliac disease associated
with severe osteoporosis1 and later in 2013, in patients presenting with rheumatoid
arthritis, systemic lupus erythematosus, spondyloarthritis and osteoporosis2.
 These findings suggest a role for a-OPGAb as primary cause of high bone turnover.
 We aimed to develop an enzyme linked immunosorbent assay (ELISA) for detection and
quantification of a-OPGAb in patient serum samples.
Introduction
RANK/RANKL/OPG signalling pathway.
The RANK/RANKL/OPG signalling pathway is
essential for osteoclastogenesis.
Osteoprotegerin (OPG) is a decoy receptor for
RANKL. By binding to RANKL, OPG blocks
RANKL-RANK interaction, inhibiting the
differentiation of the osteoclast precursor into
a mature osteoclast and thereby protecting the
skeleton from excessive bone resorption.
Development of a sandwich-like assay:
Schematic of a-OPGAb assay principle and table of reagents.
 Typical standard curve
antibody against human a-
OPGAb. Circulating antibody
concentration is calculated
against a 4-Parameter Logistic
equation (Typical obtained
using a polyclonal r2=0.9916).
 Finalised protocol: using a sample/standard and control volume of 50µL which are
incubated for 3hrs at RT, the assay has been developed to be performed within a day
(6.5hrs)
 The format of the assay (volumes, temperatures and times) are convenient to
transpose it onto an automated platform.
Case study
Box-Plot showing the distribution of a-OPGAb in healthy women and men and in 
patients with high TPO (green). Mrs JY (  ) showed elevated levels of serum a-OPGAb.
History- Mrs JY, 49, presented with multiple bone aches involving mainly the axial skeleton
and severe joint pain (hips, knees, wrists and small joints of the hands). Biochemical
investigations detected an adjusted calcium of 3.56mmol/L (ref range 2.15-2.60mmol/L),
markedly elevated bone turnover CTX 3.95µg/L (0.1-0.5µg/L), P1NP 1200µg/L (19-89µg/L),
Bone ALP 224IU/L (14-50IU/L) but all other investigations including autoantibody screen
were normal and joint aspiration was negative. Following zoledronate therapy, adjusted
calcium normalised at 2.34mmol/L and bone turnover decreased, CTX 0.97µg/L, P1NP
175µg/L, bone ALP 64IU/L.
Conclusions
 Autoantibodies have been shown to be present in the blood of patients with
autoimmune diseases such as rheumatoid arthritis3-5, diabetes mellitus6, lupus7,8 and
retrospectively in patients with primary Sjögren syndrome9 prior to development of any
symptoms but also before development of tumors10.
Prevalence of α-OPGAb in healthy individuals suggests a possible autoimmune cause of
metabolic bone diseases with presentation of pre-symptomatic antibodies. α-OPGAb in
young (<50yrs) and healthy individuals tended to be present in individuals with high
bone formation markers (PINP) rather than bone degradation markers (CTX). The
subjects being young army volunteers subjected to heavy physical training a high bone
turnover is not surprising. However, these results suggest that autoantibodies against
osteoprotegerin in healthy individuals may be present in a non functional or
dysfunctional state at this stage and may become functional later due to changes in the
antibodies themselves or dysregulation in the OPG/RANK/RANKL/α-OPGAb system.
Further study is needed to answer this question.
 We developed a novel plate-based ELISA assay for the detection and measurement of α-
OPGAb in human serum. The assay showed good assay characteristics, suitable for use in
research and clinical hospital laboratories. However we are limited in using a standard
antibody of animal origin (rabbit) allowing us to only perform a relative quantification of
α-OPGAb in human serum.
 The novel ELISA for detection and measurement of α-OPGAb is a potential diagnostic
tool for patients with high bone turnover and for clinicians to identify appropriate
treatment options. When α-OPGAb are present, suppressing the regulatory effect of
OPG on the activation of RANK by RANKL, an appropriate treatment may be Denosumab
(licenced osteoporosis treatment under the trade name Prolia and Xgeva) which is an
antibody to RANKL.
Patients with 
high TPO
Cut-Off limit:
96ng/mL
women men
a
-O
P
G
 a
n
ti
b
o
d
y]
 r
an
ge
 (
n
g
/m
L)
References:
1-Riches et al. (2009) N Engl J Med:361 pp1459-65. 2-Hauser et al. (2013) Bone Abstracts: 1 pp383. 3-Nielen et al. (2004) Arthritis
and rheumatism:50 pp380-386. 4-Jorgensen et al.(2008) Annals of the rheumatic diseases:67 pp860-866.5- Dahlqvist (2003) ACP
journal club 139 pp50. 6-Whittingham et al. (1997) Diabetic medicine : a journal of the British Diabetic Association:14 pp678-
685.7-Eriksson et al. (2011) Arthritis research & therapy:13 pp30. 8-Arbuckle et al. (2003) N Engl J Med:349 pp1526-1533. 9-
Jonsson et al. (2013) JAMA:310 pp1854-1855. 10-Conrad & Bachmann (2005) Pre-symptomatic Tumor Diagnostics Vol.1 pp22-77.
Measurement of Autoantibodies Against Osteoprotegerin 
in Adult Human Serum: 
Development of a Novel ELISA  Assay
Corresponding author: i.piec@uea.ac.uk
Reagent Provider
MaxisorpTM F8 ThermoFisher Scientific, Loughborough, UK
Coating Buffer AbD Serotec, Kindlington, UK
Blocking Buffer AbD Serotec, Kindlington, UK
rhTNFRSF11B Novoprotein, Summit, USA
STD: α-OPGAb (rabbit) Abnova, Taipei, Taiwan
CONJ: Donkey α-rabbit 
IgG, Biotin
ThermoFisher Scientific, Loughborough, UK
SA-HRP
Jackson ImmunoResearch Lab., West Grove, 
USA
TMB Sigma Aldrich, Dorset, UK
